Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany..
PURPOSE: People with hematologic malignancies have a significantly higher risk of developing severe and protracted forms of SARS-CoV-2 infection compared to immunocompetent patients, regardless of vaccination status.
RESULTS: We describe two cases of prolonged SARS-CoV-2 infection with multiple relapses of COVID-19 pneumonia in patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. The aim is to highlight the complexity of SARS-CoV-2 infection in this fragile group of patients and the necessity of evidence-based strategies to treat them properly.
CONCLUSIONS: Patients with hematological malignancies treated with bendamustine and anti-CD20 antibodies had a significant risk of prolonged and relapsing course of COVID-19. Specific preventive and therapeutic strategies should be developed for this group of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Infection - 51(2023), 5 vom: 19. Okt., Seite 1577-1581 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Franceschini, Erica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 23.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s15010-023-02039-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355805707 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355805707 | ||
| 003 | DE-627 | ||
| 005 | 20231226065123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-023-02039-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355805707 | ||
| 035 | |a (NLM)37076752 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Franceschini, Erica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 23.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. | ||
| 520 | |a PURPOSE: People with hematologic malignancies have a significantly higher risk of developing severe and protracted forms of SARS-CoV-2 infection compared to immunocompetent patients, regardless of vaccination status | ||
| 520 | |a RESULTS: We describe two cases of prolonged SARS-CoV-2 infection with multiple relapses of COVID-19 pneumonia in patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. The aim is to highlight the complexity of SARS-CoV-2 infection in this fragile group of patients and the necessity of evidence-based strategies to treat them properly | ||
| 520 | |a CONCLUSIONS: Patients with hematological malignancies treated with bendamustine and anti-CD20 antibodies had a significant risk of prolonged and relapsing course of COVID-19. Specific preventive and therapeutic strategies should be developed for this group of patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-CD20 | |
| 650 | 4 | |a Bendamustine | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunosuppressed patient | |
| 650 | 4 | |a Lymphoma | |
| 650 | 4 | |a Obinutuzumab | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Bendamustine Hydrochloride |2 NLM | |
| 650 | 7 | |a 981Y8SX18M |2 NLM | |
| 650 | 7 | |a obinutuzumab |2 NLM | |
| 650 | 7 | |a O43472U9X8 |2 NLM | |
| 700 | 1 | |a Pellegrino, Mariachiara |e verfasserin |4 aut | |
| 700 | 1 | |a Todisco, Vera |e verfasserin |4 aut | |
| 700 | 1 | |a Dolci, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Bettelli, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Meschiari, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Bedini, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Fregni-Serpini, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Grottola, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Guaraldi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Pecorari, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Sarti, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Luppi, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Perno, Carlo Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Mussini, Cristina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d 1973 |g 51(2023), 5 vom: 19. Okt., Seite 1577-1581 |w (DE-627)NLM00001740X |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2023 |g number:5 |g day:19 |g month:10 |g pages:1577-1581 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s15010-023-02039-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2023 |e 5 |b 19 |c 10 |h 1577-1581 | ||